Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.0.1370262
European Journal of Endocrinology, Vol 137, Issue 3, 262-266
Copyright © 1997 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sachse, R
Right arrow Articles by Hensen, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sachse, R
Right arrow Articles by Hensen, J

Articles

Absence of angiotensin II type 1 receptor gene mutations in human adrenal tumors

R Sachse, XJ Shao, A Rico, U Finckh, A Rolfs, M Reincke, and J Hensen

Department of Medicine 1, University of Erlangen, Germany.

Regulatory actions of angiotensin II (AngII), which is involved in the pathophysiology of hypertension and also participates in cell proliferation and cell differentiation, are mainly mediated by AngII type 1 (AT1) receptor. Recently, activating mutations of receptors causing hyperfunctioning endocrine diseases have been described in the case of the TSH and LH receptors, implicating that such mutations might occur in other G-protein-coupled receptors. Furthermore it seems to be possible that genetic variations of AT1 receptor have an influence upon the action of AngII. Therefore, we searched by sequence analysis of the coding region of AT1 receptor gene for activating mutations and genetic polymorphisms in 56 human adrenal tumors (16 aldosterone-producing adenomas, 10 cortisol-producing adenomas, 1 aldosterone-producing carcinoma, and 29 incidentalomas). We were not able to identify any activating mutation in the coding region of AT1 receptor gene. We conclude that activating mutations of the AT1 receptor are not a major cause of the development of adrenal adenomas, if at all. In addition, polymorphic subtypes of AT1 receptor do not seem to play a major role in the pathogenesis of these tumors, even though a tendency towards a higher frequency of the polymorphic base substitution at position 573 (T573-->C) in cortisol-producing tumors needs to be further evaluated.


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
H.-W. Chang, T.-S. Chu, H.-Y. Huang, S.-C. Chueh, V.-C. Wu, Y.-M. Chen, B.-S. Hsieh, and K.-D. Wu
Down-Regulation of D2 Dopamine Receptor and Increased Protein Kinase C{micro} Phosphorylation in Aldosterone-Producing Adenoma Play Roles in Aldosterone Overproduction
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1863 - 1870.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. A. Koch, K. Pacak, and G. P. Chrousos
The Molecular Pathogenesis of Hereditary and Sporadic Adrenocortical and Adrenomedullary Tumors
J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5367 - 5384.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
S. R. Bornstein, C. A. Stratakis, and G. P. Chrousos
Adrenocortical Tumors: Recent Advances in Basic Concepts and Clinical Management
Ann Intern Med, May 4, 1999; 130(9): 759 - 771.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 European Society of Endocrinology.